Time to onset of hypothyroidism after first treatment with immune checkpoint inhibitors in the combination therapy and monotherapy groups. Time to onset.

Slides:

Advertisements

Similar presentations

Melanoma donor (MD) NK cells are functionally impaired/exhausted.

Advertisements

CD25 expression is associated with unfavorable clinical outcome.

Nonclassical monocytes are specifically depleted following M-CSFR inhibition and these cells are highest in PD-L1 expression in blood of mice during therapy.

The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

High-throughput combination drug screening to nominate potent drug combinations. High-throughput combination drug screening to nominate potent drug combinations.

Pharmacologic inhibitors of PI3Kγ suppress PDAC growth and metastasis.

Quantification of MHC-I, β2m, and T-cell subsets.

UK improves survival. UK improves survival. Following SNx, rats were divided into SNx untreated (disease, n=24; half those remaining were.

Figure 1 BG-12 treatment reduced total circulating B cells and had variable effects on memory B cells BG-12 treatment reduced total circulating B cells.

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

GLP-1 and gastrin combination therapy induces immunoregulatory cell activity in NOD mice. GLP-1 and gastrin combination therapy induces immunoregulatory.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

Learning rates and CR latency data for mice trained at trace 50–350 or trace 50–450. Learning rates and CR latency data for mice trained at trace 50–350.

Frequency and kinetics of killer cell apoptosis are dependent on functional conjugations with multiple NALM-6 tumor cells. Frequency and kinetics of killer.

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

Diagnostic plots of the TGI PKPD model fitted to the A677 TGI data.

Expression analysis of IGFBP-3 using human whole-genome microarray.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

MiR-520d-3p is an independent positive prognostic factor in ovarian cancer. miR-520d-3p is an independent positive prognostic factor in ovarian cancer.

The presence of soluble IL12p70 during moDCpoly stimulation of KIRnegNKG2Aneg cells results in a dominant population of multifunctional NKG2Apos NK cells.

Progastrin expression in colonic tissues and Kaplan–Meier survival curves. Progastrin expression in colonic tissues and Kaplan–Meier survival curves. A,

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.

CD94/NKG2A+ TILs lack tissue resident CD103 marker.

AXL is not expressed in human prostate tumors.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Presentations of thyroid disorders after receiving immune checkpoint inhibition combination therapy or monotherapy. Presentations of thyroid disorders.

Pre- and post-vorinostat values of ER-related gene expression using the Oncotype DX 21-gene assay. Pre- and post-vorinostat values of ER-related gene expression.

Pre- and post-vorinostat values of proliferation-associated gene expression using the Oncotype DX 21-gene assay. Pre- and post-vorinostat values of proliferation-associated.

Immune activity and neopeptide load correlate across tumor types.

Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. Personalized, 16-plex assays accurately detect ctDNA ahead of clinical.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

Duration of treatment and intervals of radiographic and ctDNA response

PAP- and PA2024-specific CTLs at week 0 (prior to sipuleucel-T infusion) and at weeks 6 and 26 post–sipuleucel-T treatment. PAP- and PA2024-specific CTLs.

M-CSFR inhibition decreases tumor-associated macrophages in mesothelioma and improves the DC therapy induced CD8+ T-cell phenotype. M-CSFR inhibition decreases.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

PSMA expression in pre- and posttreatment prostate carcinoma serum.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

Lesions and healthy organs dosimetry.

Selected overview of clinical trials evaluating FGFR signaling–targeted therapies currently under development (monotherapy). Selected overview of clinical.

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B)

CPI-444 enhances T-cell activation in MC38 tumors.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.

Monocytes from melanoma patients are unresponsive to TLR3 agonists.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Inhibition of CD20 mRNA expression by ibrutinib correlates with reduced NF-κB activity. Inhibition of CD20 mRNA expression by ibrutinib correlates with.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Transfection efficiency and PicoGreen cell survival assays.

Nanostring analysis of tumors after ILI and after combination limb infusion and ipilimumab. Nanostring analysis of tumors after ILI and after combination.

Progression and survival analysis.

In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways. In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

Cumulative incidences of MR4

TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. A,

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

MDSC population in patient peripheral blood.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

Epithelial and stromal percentage clusterin staining in normal nonadjacent colonic tissue and matched tumor tissue in 202 patients with stage II colorectal.

Low-Intensity Laser Therapy is an Effective Treatment for Recurrent Herpes Simplex Infection. Results from a Randomized Double-Blind Placebo-Controlled.

RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.

Presentation transcript:

Time to onset of hypothyroidism after first treatment with immune checkpoint inhibitors in the combination therapy and monotherapy groups. Time to onset of hypothyroidism after first treatment with immune checkpoint inhibitors in the combination therapy and monotherapy groups. A, Incidence of onset of hypothyroidism in 21-day intervals, calculated by the number of new cases of hypothyroidism that occurred in that 21-day interval divided by the total number of hypothyroidism cases, expressed as a percentage. Combination therapy: n = 21; Monotherapy: n = 17. B, Median onset time (median with range) of hypothyroidism after first treatment. Patients with hypothyroidism were divided into three groups: all patients with hypothyroidism (combo n = 21; mono n = 17); patients with hypothyroidism only (combo n = 2; mono n = 8); and patients who had thyrotoxicosis followed by hypothyroidism (combo n = 19; mono n = 9). Gray dots: time to onset of hypothyroidism in each patient. Combo, combination therapy; mono, monotherapy; thyrotox: thyrotoxicosis; hypo, hypothyroidism. Significant differences were determined using the Fisher test (A) and exact Wilcoxon rank-sum test (B). Hyunju Lee et al. Cancer Immunol Res 2017;5:1133-1140 ©2017 by American Association for Cancer Research